Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01162967

Acronym

CHAGASAZOL

Enrollment

Registered

2010-07-15

Start date

2010-09-30

Completion date

2013-03-31

Last updated

2013-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chagas Disease

Brief summary

The investigators propose the evaluation of posaconazole and benznidazole in humans for the treatment of Chagas disease chronical infection. Exploratory trial of posaconazole antiparasitic activity against Trypanosoma cruzi.

Interventions

DRUGBenznidazole

Standard dosage

DRUGPosaconazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Consenting patients with serological evidence of Chagas infection and positive PCR real time

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Parasitological cure measured by a real time PCR in blood sample	12 months after starting treatment	PCR negative at the end of follow up

Secondary

Measure	Time frame	Description
Parasitological cure measured by real time PCR in blood sample	End of treatment, weeks 8, 16, 24 and 40 after treatment	substained parasitological response
Safety and tolerability of both drugs	First 2 months	—

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026